As cold chain losses continue to plague pharmaceutical companies, reliable transport has become paramount. Approximately 4% of pharmaceuticals do not arrive at their destination in usable condition due to temperature deviations. This costs companies hundreds of thousands of dollars in wasted supplies and quality analyses. For this reason, it is critical for pharmaceutical shipping companies to invest in transport containers that can maintain the exact temperatures required for their contents.

The use of high-quality cold transport containers in the pharmaceutical transportation process is essential for ensuring that pharmaceutical companies can overcome the numerous shipping obstacles they face:

The most important and obvious benefit of refrigerated pharmaceutical shipping containers is their ability to maintain appropriate temperatures throughout the transportation cycle (or even for static storage steady temperature control at a production facility). A temperature variation of as little as two degrees can be enough to spoil the product, which could result in losses totaling hundreds or thousands of dollars for smaller orders and millions for larger shipments.

Today, pharmaceutical reefer units are available that will control the temperature of pharmaceutical products and allow the shipper to monitor it throughout the journey. These containers are equipped with sensors that can detect small temperature variations.

Klinge offers several pharmaceutical transport container options to meet the temperature requirements of pharma products from -65°C up to 20°C, including dual-redundant options with optional integral power packs and remote monitoring. This enables the shipper to maintain a consistent temperature throughout the journey regardless of the atmospheric conditions.

US Telephone: + 1 717 840 4500
Telefax: +1 717 840 4501

Go to article: Home | The absence of antivenomGo to article: In this issueGo to article: Daiichi JitsugyoGo to article: ContentsGo to article: Capsugel Company InsightGo to article: CapsugelGo to article: NewsGo to article: Scandinavian Health Ltd.Go to article: International Cannabis and Cannabinoid Institute (ICCI) Company InsightGo to article: International Cannabis and Cannabinoid Institute (ICCI)Go to article: The pharma industry briefingGo to article: TSS Company InsightGo to article: TSS ABGo to article: Action Medical Research: celebrating decades of discovery Go to article: Swiss WorldCargoGo to article: Gerteis Company InsightGo to article: GerteisGo to article: Moehs Iberica SLGo to article: Owen MumfordGo to article: How government policy has shaped China’s pharma phenomenonGo to article: HOF Sonderanlagenbau Company InsightGo to article: HOF SonderanlagenbauGo to article: Novo NordiskGo to article: Snake venom in pharma; access to antivenom is a topic that needs attentionGo to article: Phoenix Group Company InsightGo to article: Phoenix Group Go to article: ME Logistic ServicesGo to article: Discussing drug policy reform with psychedelics campaigner Amanda FeildingGo to article: Finnair Cargo | Company InsightGo to article: Finnair CargoGo to article: Aseptic TechnologiesGo to article: False flags: are search engines benefiting rogue online pharmacies?Go to article: CBDepot Company InsightGo to article: CBDepotGo to article: Wilco Company Insight Go to article: WilcoGo to article: The Mighty: how patients and pharma align in the age of social media Go to article: Pharma Support Services Company InsightGo to article: Pharma Support ServicesGo to article: MicronovaGo to article: Inside Italy’s pharmaceutical industry Go to article: KlingeGo to article: BEAGo to article: Erdmann Design SwitzerlandGo to article: Inside the UK’s first vaccines innovation centreGo to article: AralabGo to article: Applikon BiotechnologyGo to article: BaxterGo to article: NymiGo to article: Fostering closer collaboration between manufacturing & regulatory functionsGo to article: EmisphereGo to article: SephaGo to article: Contract Pharmaceuticals Limited CanadaGo to article: EventsGo to article: Pfanstiehl Company InsightGo to article: PfanstiehlGo to article: Next issueGo to article: PolpharmaGo to article: BioAdvice